Prospera Financial Services Inc Decreases Stake in Moderna, Inc. (NASDAQ:MRNA)

Prospera Financial Services Inc trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 81.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,083 shares of the company’s stock after selling 13,673 shares during the period. Prospera Financial Services Inc’s holdings in Moderna were worth $206,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $26,000. Family Firm Inc. purchased a new position in shares of Moderna in the 2nd quarter valued at $33,000. Bank & Trust Co acquired a new stake in Moderna during the 2nd quarter worth $36,000. Hanseatic Management Services Inc. purchased a new stake in Moderna in the second quarter valued at $48,000. Finally, Plato Investment Management Ltd boosted its stake in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Moderna stock opened at $43.66 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47. The company has a market cap of $16.80 billion, a P/E ratio of -7.50 and a beta of 1.69. The business has a fifty day moving average of $54.96 and a two-hundred day moving average of $93.71.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the previous year, the firm earned ($1.39) earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. As a group, analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Wolfe Research started coverage on Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and cut their target price for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Sanford C. Bernstein began coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $84.00.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 2,930 shares of company stock valued at $217,170 in the last quarter. 15.20% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.